Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
168
-
Total 13F shares, excl. options
-
75.4M
-
Shares change
-
-492K
-
Total reported value, excl. options
-
$972M
-
Value change
-
-$15M
-
Number of buys
-
72
-
Number of sells
-
-98
-
Price
-
$12.91
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q1 2022
207 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q1 2022.
Coherus Oncology, Inc. - Common Stock (CHRS) has 168 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.4M shares
of 115M outstanding shares and own 65.3% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12.1M shares), Temasek Holdings (Private) Ltd (7.38M shares), JPMORGAN CHASE & CO (6.58M shares), ALLIANCEBERNSTEIN L.P. (5.81M shares), STATE STREET CORP (5.16M shares), VANGUARD GROUP INC (4.74M shares), PERCEPTIVE ADVISORS LLC (4.7M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.19M shares), and AMERIPRISE FINANCIAL INC (1.86M shares).
This table shows the top 168 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.